Carbapenem therapy for bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae

被引：29

作者：

Lee, Nan-Yao ^{[3
,4
]}

Huang, Wei-Han ^{[1
]}

Tsui, Ko-Chung ^{[1
]}

Hsueh, Po-Ren ^{[1
,2
]}

Ko, Wen-Chien ^{[3
,4
]}

机构：

[1] Natl Taiwan Univ, Coll Med, Natl Taiwan Univ Hosp, Dept Lab Med, Taipei 10764, Taiwan

[2] Natl Taiwan Univ, Coll Med, Dept Internal Med, Natl Taiwan Univ Hosp, Taipei, Taiwan

[3] Natl Cheng Kung Univ Hosp & Med Coll, Dept Internal Med, Tainan, Taiwan

[4] Natl Cheng Kung Univ Hosp & Med Coll, Ctr Infect Control, Tainan, Taiwan

来源：

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE | 2011年 / 70卷 / 01期

关键词：

ESBL; Escherichia coli; Klebsiella pneumoniae; Bacteremia; Carbapenem; BLOOD-STREAM INFECTIONS; RISK-FACTORS; ERTAPENEM; ENTEROBACTERIACEAE; MORTALITY;

D O I：

10.1016/j.diagmicrobio.2010.12.008

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

For 244 patients with bacteremia due to extended-spectrum beta-lactamase (ESBL) producing Escherichia coli or Klebsiella pneumoniae treated by ertapenem (73, 29.9%) or either imipenem or meropenem (171, 70.1%), the therapeutic efficacy was evaluated. Ertapenem therapy was effective for patients with ESBL-producing E. coli or K. pneumoniae bacteremia in terms of mortality and microbiological responses, as compared with imipenem or meropenem. (C) 2011 Elsevier Inc. All rights reserved.

引用

页码：150 / 153

页数：4

共 15 条

[1]

[Anonymous], MANDELL DOUGLAS BENN

[2] Efficacy of ertapenem for consolidation therapy of extended-spectrum β-lactamase-producing gram-negative infections:: A case series report [J].

Berg, Melody L. ;

Crank, Christopher W. ;

Philbrick, Alexander H. ;

Hayden, Mary K. .

ANNALS OF PHARMACOTHERAPY, 2008, 42 (02) :207-212

[3] Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia: a commentary [J].

Chow, JW ;

Yu, VL .

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 1999, 11 (01) :7-12

[4]

CLSI, 2006, informational supplement M100-S16, V26

[5] Bactericidal activities of meropenem and ertapenem against extended-spectrum-β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model [J].

DeRyke, C. Andrew ;

Banevicius, Mary Anne ;

Fan, Hong Wei ;

Nicolau, David P. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (04) :1481-1486

[6] In vitro evaluation of ertapenem (MK-0826), a long-acting carbapenem, tested against selected resistant strains [J].

Jones, RN .

JOURNAL OF CHEMOTHERAPY, 2001, 13 (04) :363-376

[7] Bloodstream infections due to extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae:: Risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy [J].

Kang, CI ;

Kim, SH ;

Park, WB ;

Lee, KD ;

Kim, HB ;

Kim, EC ;

Oh, MD ;

Choe, KW .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (12) :4574-4581

[8] Risk factors for and clinical outcomes of bloodstream infections caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae [J].

Kang, CI ;

Kim, SH ;

Kim, DM ;

Park, WB ;

Lee, KD ;

Kim, HB ;

Oh, MD ;

Min, EC ;

Choe, KW .

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2004, 25 (10) :860-867

[9] Bloodstream infections by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children:: Epidemiology and clinical outcome [J].

Kim, YK ;

Pai, H ;

Lee, HJ ;

Park, SE ;

Choi, EH ;

Kim, J ;

Kim, JH ;

Kim, EC .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (05) :1481-1491

[10] International prospective study Klebsiella pneumoniae bacteremia:: Implications of extended-spectrum β-lactamase production in nosocomial infections [J].

Paterson, DL ;

Ko, WC ;

Von Gottberg, A ;

Mohapatra, S ;

Casellas, JM ;

Goossens, H ;

Mulazimoglu, L ;

Trenholme, G ;

Klugman, KP ;

Bonomo, RA ;

Rice, LB ;

Wagener, MM ;

McCormack, JG ;

Yu, VL .

ANNALS OF INTERNAL MEDICINE, 2004, 140 (01) :26-32

← 1 2 →